HBM Partners

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

1000Farmacie operates as a leading pharmacy marketplace in Italy, connecting a network of independent pharmacies to enable faster deliveries. It runs an online medical platform that offers a wide range of pharmaceutical products from authorized pharmacies at reasonable prices, with options for same-day delivery to any location, helping customers save time and money.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Shape Memory Medical is a medical device company based in Santa Clara, California. It specializes in developing innovative therapeutic solutions for peripheral vascular, cardiovascular, and neurovascular markets using Shape Memory Polymer technology.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Founded in 2013, Cassini Technologies is a Dutch medical device company specializing in developing innovative corneal diagnostic solutions. It pioneers smart and superior eye diagnosis tools like the Cassini Corneal Shape Analyzer and EasyScan retinal imaging system, empowering care providers worldwide to serve their patients better.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly those that have been historically overlooked. Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in antibiotics for gynecologic infections. Its lead product, Solosec (secnidazole), is a next-generation 5-nitroimidazole antibiotic designed for the one-time oral treatment of bacterial vaginosis. This drug is characterized by its enhanced pharmacokinetic properties, allowing for effective and well-tolerated delivery in a single dose. Symbiomix Therapeutics operates as a subsidiary of Lupin Inc.

APR Applied Pharma Research s.a. is a pharmaceutical company based in Balerna, Switzerland, established in 1990. It specializes in the identification, development, manufacturing, and licensing of healthcare products across various therapeutic areas, including cancer supportive care, CNS disorders, dermatology, gynecology, and pain management. The company focuses on creating oral and topical formulations, offering a range of prescription and consumer healthcare products such as treatments for acute pain, cough, cold, and more. APR's innovative drug delivery systems and science-driven formulation technology enable it to address unmet medical needs, particularly in specialized therapeutic areas and rare diseases. With a strategic focus on markets in Europe and the United States, as well as rapidly growing regions like China, Russia, and Latin America, APR aims to improve the lives of patients and empower families through novel approaches to disease management.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Odyssey Thera, Inc. is a biopharmaceutical company based in San Ramon, California, dedicated to identifying and developing innovative therapies for cancer treatment. The company employs a cellular pharmacology strategy to decipher biologically-relevant pathways in living human cells, enhancing the processes of target and drug discovery. Odyssey Thera's product pipeline features small molecule inhibitors that target crucial signaling nodes in human cancer cells. Originally incorporated as Odyssey Pharmaceuticals in 2002, the company has evolved to focus on advancing methods for environmental chemical toxicity assessment alongside its therapeutic development efforts.

Reha Technology AG is a Swiss company specializing in the design, manufacture, and global distribution of advanced robotic-assisted systems for neurorehabilitation. Founded in 2012 and headquartered in Olten, Switzerland, the company focuses on developing devices that enhance the quality of life for individuals affected by neurological movement disorders, injuries, or disabilities. Its flagship product, the G-EO System, is designed for gait rehabilitation and features capabilities that realistically simulate stair climbing. Reha Technology aims to empower patients by improving their functional abilities and skills necessary for personal self-care and independence in daily life. With a worldwide distributor network, the company has established direct operations in the United States and India, and it plans to expand further into Latin America.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

Newron Pharmaceuticals is a clinical‑stage biopharmaceutical company headquartered in Bresso near Milan, Italy, with a subsidiary in Morristown, New Jersey. The company develops therapies for central and peripheral nervous system disorders and pain. Its approved product, Xadago (safinamide), treats Parkinson’s disease and is marketed in the EU, Switzerland, the United States, and key Asian markets through partners such as Zambon, WorldMeds, and Meiji Seika/Eisai. Newron’s pipeline includes sarizotan for Rett syndrome, evenamide as a potential add‑on therapy for positive symptoms of schizophrenia, and ralfinamide for rare neuropathic pain conditions. The company conducts research and development in Italy and the United States and is listed on the SIX Swiss Exchange.

Anadys Pharmaceuticals is a biopharmaceutical company based in San Diego, California, focused on developing treatments for chronic hepatitis C viral infections. The company is primarily working on ANA598, a direct-acting antiviral agent designed to inhibit the hepatitis C virus. Additionally, Anadys is investigating ANA773, an oral small-molecule inducer of endogenous interferons that activates the Toll-like receptor 7 pathway. Founded in 1992, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

AGY Therapeutics is a biopharmaceutical company based in South San Francisco, California, founded in 1998. The company specializes in discovering, developing, and commercializing treatments for diseases of the central nervous system (CNS). Its focus areas include neurodegenerative diseases, CNS injuries, stroke, cognitive diseases, and schizophrenia. AGY Therapeutics has a pipeline of novel therapeutic programs, both in clinical and preclinical development, aimed at addressing significant unmet medical needs. The company uses its proprietary platform for functional gene discovery and mapping specific pathways underlying CNS diseases to identify potential target proteins that can modulate disease progression. This approach is designed to pave the way for innovative CNS therapeutics.

Aspreva Pharmaceuticals Corp is a pharmaceutical company based in Victoria, British Columbia, dedicated to developing and commercializing new indications for existing drugs aimed at underserved patient populations. The company specializes in identifying late-stage and approved medications that have the potential for significant therapeutic benefits in less common diseases. Through a strategy known as "indication partnering," Aspreva collaborates with other pharmaceutical and biopharmaceutical companies to gain rights for the development of these drugs in new therapeutic areas. This approach encompasses clinical research, regulatory approvals, and the commercialization of products tailored for complex diseases and specialized patient groups. By focusing on innovative therapeutic solutions, Aspreva aims to address unmet medical needs and improve patient outcomes.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases. Founded in 1996 by Professor Sir David Lane, the company focuses on oral therapies that target various phases of cell cycle control.

Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically aimed at treating various types of cancer. Founded in 1997 and based in Santa Monica, California, Agensys develops innovative products targeting tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. The company is dedicated to providing effective treatment options for patients battling these cancers. In 2007, Agensys became a subsidiary of Astellas Pharma US, Inc., further enhancing its capabilities in the oncology therapeutic space.

Syrrx Inc is a biotechnology company that specializes in the development of novel small molecule drugs aimed at treating cancer, metabolic diseases, and inflammation. By leveraging its expertise in high-throughput structural biology, Syrrx is able to determine the three-dimensional structures of drug targets that have been validated in human clinical trials. This foundational work supports their iterative, structure-based drug design programs, which efficiently generate potential drug candidates. The company has established partnerships for the development and commercialization of its designed human dipeptidyl peptidase IV (DPP IV) inhibitors for the treatment of type 2 diabetes and other significant diseases. Additionally, Syrrx has a strategic alliance focused on discovering and early developing inhibitors that target human histone deacetylases (HDACs) and 11β-hydroxysteroid dehydrogenase type 1 (HSD1), further expanding its therapeutic portfolio.